Sarepta Therapeutics概念验证数据:单剂量SRP-1001与SRP-1003可降低靶蛋白或mRNA水平

美股速递
Yesterday

最新概念验证研究数据显示,Sarepta Therapeutics研发的SRP-1001和SRP-1003在单次给药后,能有效降低目标蛋白或信使核糖核酸(mRNA)的表达水平。这一突破性进展为相关疗法的后续开发奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10